Physiomics PLC Issue of Options (1982U)
27 Marzo 2019 - 7:00AM
UK Regulatory
TIDMPYC
RNS Number : 1982U
Physiomics PLC
27 March 2019
27(th) March 2019
Physiomics plc
("Physiomics") or ("the Company")
Issue of Options
The Company considers that the award of options linked to
company performance are critical to the incentivisation of its
senior employees and to ensure that there is alignment between
management and shareholders. To this end, the Company today
confirms that it has agreed to issue share options to its
directors, as detailed in this announcement. Each option forming
part of this award is exercisable at a price of 3.16p, being the
greater of (i) the average closing price for the three dealing days
immediately preceding the date of grant; and (ii) the closing price
on the dealing day immediately prior to the date of grant.
1. 400,000 share options over ordinary shares in the Company
have been granted to Dr James Millen under the Enterprise
Management Initiative Scheme ("EMI")
2. 267,000 share options over ordinary shares in the Company
have been granted to Dr Christophe Chassagnole under the Enterprise
Management Initiative Scheme ("EMI")
The options vest based on a combination of performance and
time-based criteria and can be exercised within 10 years of the
date of grant.
Following this issue, Jim Millen will hold options over
2,373,923 ordinary shares of the Company and Christophe Chassagnole
will hold options over 1,879,533 ordinary shares in the Company in
accordance with the table below:
Option holder # Options Exercise Expiry date
price(p)
--------------- ---------- ---------- ------------
J Millen 1,453,923 2.500 27-Feb-27
520,000 5.350 26-Mar-28
400,000 3.160 26-Mar-29
C Chassagnole 118,565 40.000 29-Feb-20
32,331 34.000 08-Nov-21
129,381 13.200 11-Feb-23
322,615 6.167 23-Mar-25
659,641 2.500 27-Feb-27
350,000 5.350 26-Mar-28
267,000 3.160 26-Mar-29
In addition, Jim Millen owns 444,641 ordinary shares (equivalent
to 0.62% of the currently issued share capital) and Christophe
Chassagnole owns 417,008 ordinary shares (equivalent to 0.58% of
the currently issued share capital).
The total number of shares in issue remains 71,910,394 Ordinary
Shares with voting rights attached (one vote per Share). There are
no Shares held in treasury. This total voting rights figure may be
used by shareholders as the denominator for the calculations by
which they will determine whether they are required to notify their
interests in, or a change to their interest in, Physiomics under
the Disclosure and Transparency Rules.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr James Millen
--------------------------------------------------------------- ------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------------
a) Position/status CEO
--------------------------------------------------------------- ------------------------------
b) Initial notification/ Amendment Initial
--------------------------------------------------------------- ------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-----------------------------------------------------------------------------------------------
a) Name Physiomics PLC
--------------------------------------------------------------- ------------------------------
b) LEI 213800A71DSZ6ABMTQ91
--------------------------------------------------------------- ------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Options over Ordinary Shares
Identification code
GB00BDR6W943
--------------------------------------------------------------- ------------------------------
b) Nature of the transaction Issue of options
--------------------------------------------------------------- ------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
3.16 pence 400,000
----------
--------------------------------------------------------------- ------------------------------
d) Aggregated information
* Aggregated volume 400,000
3.16 pence
* Price
--------------------------------------------------------------- ------------------------------
e) Date of the transaction 27 March 2019
--------------------------------------------------------------- ------------------------------
f) Place of the transaction London, AIM
--------------------------------------------------------------- ------------------------------
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Christophe Chassagnole
--------------------------------------------------------------- ------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------------
a) Position/status COO
--------------------------------------------------------------- ------------------------------
b) Initial notification/ Amendment Initial
--------------------------------------------------------------- ------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-----------------------------------------------------------------------------------------------
a) Name Physiomics PLC
--------------------------------------------------------------- ------------------------------
b) LEI 213800A71DSZ6ABMTQ91
--------------------------------------------------------------- ------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Options over Ordinary Shares
Identification code
GB00BDR6W943
--------------------------------------------------------------- ------------------------------
b) Nature of the transaction Issue of options
--------------------------------------------------------------- ------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
3.16 pence 267,000
----------
--------------------------------------------------------------- ------------------------------
d) Aggregated information
* Aggregated volume 267,000
3.16 pence
* Price
--------------------------------------------------------------- ------------------------------
e) Date of the transaction 27 March 2019
--------------------------------------------------------------- ------------------------------
f) Place of the transaction London, AIM
--------------------------------------------------------------- ------------------------------
About Physiomics plc
Physiomics plc (AIM: PYC) is a solutions provider to the
R&D-based pharmaceutical and biotechnology industry with a
focus on oncology. The Company's Virtual Tumour technology uses
computer modelling to predict the effects of cancer drugs and
treatments to improve the success rate of drug discovery and
development projects while reducing time and cost. The predictive
capability of Virtual Tumour has been confirmed by 70 projects,
involving over 30 targets and 60 drugs.
Based in Oxford, UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics' senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals.
The information contained within this announcement is deemed by
the Company to constitute inside information under the Market Abuse
Regulation (EU) No. 596/2014.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUBVARKKAOUAR
(END) Dow Jones Newswires
March 27, 2019 09:00 ET (13:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024